US and WO patent update for the week ending 06/05

US and WO kinase patents have been updated for this week at KinaseCentral.com

Novartis VEGF kinase inhibitor NVP-BAW2881 inhibits endothelial cell function and inflammation

Novartis’ VEGF kinase inhibitor NVP-BAW2881 has been shown to inhibit the proliferation, migration and tube formation of endothelial cells in vitro and the formation of blood and lymphatic vessels in a transgenic model of psoriasis

Dasatinib delays multiple myeloma cell growth and angiogenesis in vivo via PDGFRand Src inhibition

University of Bari and Milan researchers have shown that dasatinib (BMS-354825/Sprycel) delays multiple myeloma cell growth and angiogenesis in vivo via PDGFRbeta and Src inhibition

Novel VEGFR inhibitors described

Researchers from Eberhard-Karls University, ProQinase GmbH and Johannes Gutenberg University describe new pyrrole-2-one based VEGFR2/VEGFR3 inhibitors with with IC50s of 31 and 37 nM respectively.

Imatinib in C-Kit or PDGFR-β expressing metastatic breast cancer

Imatinib mesylate was tested in patients with metastatic breast cancer expressing PDGFR or c-kit. No objective responses were observed and Imatinib given alone does not appear to demonstrate clinical activity